EMA and FDA unveil joint AI principles to transform drug revelopment
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Experts caution that realizing AI’s potential requires careful management and risk mitigation
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
Subscribe To Our Newsletter & Stay Updated